Clinical area: Respiratory - AI and novel technologies in lung function measurement

Why:

• Lung disease, including chronic obstructive pulmonary disease (COPD), asthma and pneumonia, is the third biggest cause of death in England (after cancer and cardiovascular disease).
• There are well established technologies to measure lung function. NICE guidelines suggest that spirometry testing should be run for any diagnosis of either asthma or COPD, and FeNO testing is not extensively used, despite being recommended by NICE.
• Capacity to test and interpret lung function is insufficient to meet clinical need. Technology has an opportunity to enhance diagnostic capacity across lung diseases earlier on in the pathway, closer to home, or in communities currently less well served.

Products in scope:

Digital health technologies should meet the following criteria:

• Are intended for use by people of all age ranges.
• Technology can be used to interpret or perform and interpret lung function.
• Technologies may incorporate elements of AI into the interpretation process.
• Meet the standards within the digital technology assessment criteria (DTAC), including the criteria to have a CE or UKCA mark where required.
• Products may also be considered if they are actively working towards required CE or UKCA mark, have been deployed in a small number (2-10) of NHS sites or comparable clinical providers internationally.

If your product is in development, the NHS Innovation Service can help support you meet these standards and other requirements.

Further information:

If you have an innovation that meets that need, create an NHS Innovation Service account and fill in your innovation record to start receiving support for this innovation.